These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 18403395

  • 1. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 2. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 4. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 5. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [Abstract] [Full Text] [Related]

  • 7. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
    [Abstract] [Full Text] [Related]

  • 8. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R.
    Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
    [Abstract] [Full Text] [Related]

  • 9. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 11. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 12. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P, Stipa E, La Presa M, Bianchi M, Di Giulio C, Stasi R, Amadori S.
    Recenti Prog Med; 2002 Nov; 93(7-8):421-7. PubMed ID: 12138687
    [Abstract] [Full Text] [Related]

  • 13. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
    Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US.
    Haematologica; 2005 Feb; 90(2):281-3. PubMed ID: 15710595
    [Abstract] [Full Text] [Related]

  • 14. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 15. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
    Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R.
    Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
    [Abstract] [Full Text] [Related]

  • 16. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M.
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [Abstract] [Full Text] [Related]

  • 17. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study Group.
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [Abstract] [Full Text] [Related]

  • 18. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
    Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA.
    Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
    [Abstract] [Full Text] [Related]

  • 19. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 20. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
    Narang M, Penner JA, Williams D.
    Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.